Latest News for: bcma

Edit

2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma

PR Newswire 29 Sep 2026
IBI3003 is a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3 ... Patients with prior BCMA- and/or GPRC5D-targeted therapy were also eligible for enrollment.
Edit

2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206

The Facts 27 Sep 2026
— Late-breaking oral presentation of first-in-human data ...
Edit

2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T

PR Newswire 25 Sep 2026
the median time to peak expansion was day 15 (range 8–22); the median peak CAR transgene copy number was 112,981.7 copies/μg DNA; soluble BCMA (sBCMA) levels declined below the limit of detection in all 9 patients after infusion.
  • 1

Article Search

tools
×
×
×
×